Abstract
The COVID-19 (here specifically called Worldwide Acute Respiratory Syndrome, WARS) pandemic is surging worldwide. Unfortunately, no specific drug meets the urgent need to fight this pandemic, leading to thousands of deaths. The theory of host-directed therapies (HDTs) is viewed as the ideal means to rephrase the treatment of infectious diseases. However, related drugs based on this theory have not been identified. Previously, we realized that caffeine is the ligand of type 2 taste receptors (TAS2Rs), which play a critical role in host defense. Here, we gathered data on caffeine acting as an immunomodulator. Unexpectedly, we found that caffeine can fight WARS by acting on multiple organs, which may prevent the virus from entering the cell, stimulate the phagocytosis of macrophages, enhance breathing, and inhibit the cytokine storm. Thus, the immunoprotective effects of caffeine can improve the therapeutic outcomes in patients infected with coronavirus. Collectively, we report that caffeine, an FDA-approved, highly safe, inexpensive, and widely available drug, could be an excellent HDT for battling WARS.
Keywords: COVID-19, 2019-nCoV, SARS-CoV-2, WARS, WARS-CoV, caffeine, cytokine storm, immunomodulator, drug, TAS2R.
Current Medicinal Chemistry
Title:Rediscovery of Caffeine: An Excellent Drug for Improving Patient Outcomes while Fighting WARS
Volume: 28 Issue: 27
Author(s): Lianyong Liu, Chaobao Zhang, Juan Chen and Xiangqi Li*
Affiliation:
- Department of Endocrinology, Shanghai Gongli Hospital, The Second Military Medical University, Shanghai 200135,China
Keywords: COVID-19, 2019-nCoV, SARS-CoV-2, WARS, WARS-CoV, caffeine, cytokine storm, immunomodulator, drug, TAS2R.
Abstract: The COVID-19 (here specifically called Worldwide Acute Respiratory Syndrome, WARS) pandemic is surging worldwide. Unfortunately, no specific drug meets the urgent need to fight this pandemic, leading to thousands of deaths. The theory of host-directed therapies (HDTs) is viewed as the ideal means to rephrase the treatment of infectious diseases. However, related drugs based on this theory have not been identified. Previously, we realized that caffeine is the ligand of type 2 taste receptors (TAS2Rs), which play a critical role in host defense. Here, we gathered data on caffeine acting as an immunomodulator. Unexpectedly, we found that caffeine can fight WARS by acting on multiple organs, which may prevent the virus from entering the cell, stimulate the phagocytosis of macrophages, enhance breathing, and inhibit the cytokine storm. Thus, the immunoprotective effects of caffeine can improve the therapeutic outcomes in patients infected with coronavirus. Collectively, we report that caffeine, an FDA-approved, highly safe, inexpensive, and widely available drug, could be an excellent HDT for battling WARS.
Export Options
About this article
Cite this article as:
Liu Lianyong , Zhang Chaobao , Chen Juan and Li Xiangqi *, Rediscovery of Caffeine: An Excellent Drug for Improving Patient Outcomes while Fighting WARS, Current Medicinal Chemistry 2021; 28 (27) . https://dx.doi.org/10.2174/0929867327666201103162810
DOI https://dx.doi.org/10.2174/0929867327666201103162810 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress in Pharmacological Research of Antioxidants in Pathological Conditions: Cardiovascular Health
Recent Patents on Anti-Infective Drug Discovery Advances in the Development of Bradykinin Receptor Ligands
Current Topics in Medicinal Chemistry Stent-Based Delivered Anti-Proliferative Drugs in the Prevention of Coronary Stent Restenosis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents β-Adrenomimetic Actions in the Hypotension and Vasodilatation Induced by a Chromatographic Active Fraction from Bidens pilosa L. (Asteraceae) in Mammals
Current Bioactive Compounds Selenium and Selenoproteins: An Overview on Different Biological Systems
Current Protein & Peptide Science Reliability of Blood Pressure Patterns Defined by a Single 24-Hour Ambulatory Blood Pressure Monitoring: The Case of the Dipping/Non Dipping and Isolated Clinic Hypertension
Current Hypertension Reviews The Optimal Treatment of Severe Hypertension in Pregnancy: Update of the Role of Nicardipine
Current Pharmaceutical Biotechnology Analgesic Efficacy and Safety of Spinal Oxycodone in Total Hip Arthroplasty: A Preliminary Study
Current Medicinal Chemistry Serum Zinc and β D Glucuronidase Enzyme Level in Type 2 Diabetes Mellitus with Periodontitis
Current Diabetes Reviews New Biological Approaches in Asthma: DNA-Based Therapy
Current Medicinal Chemistry <i>Ralstonia Mannitolilytica</i>, an Unusual Pathogen in the Neonatal Intensive Care Unit: A Case of Neonatal Sepsis and Literature Review
Infectious Disorders - Drug Targets Adverse HBOC-Endothelial Dysfunction Synergism: A Possible Contributor to Adverse Clinical Outcomes?
Current Drug Discovery Technologies Diagnosing and Treating Depression in Older and Oldest Old
Current Pharmaceutical Design Cardiovascular Effects of Coumarins Besides their Antioxidant Activity
Current Topics in Medicinal Chemistry Ag/CdS Nanocomposite: An Efficient Recyclable Catalyst for the Synthesis of Novel 8-Aryl-8H-[1,3]dioxolo[4,5-g]chromene-6-carboxylic Acids under Mild Reaction Conditions
Combinatorial Chemistry & High Throughput Screening Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkins Lymphoma
Current Pharmaceutical Biotechnology The Evolution of Clostridium difficile Infection in Cancer Patients: Epidemiology, Pathophysiology, and Guidelines for Prevention and Management
Recent Patents on Anti-Infective Drug Discovery Current Drug Targets and Future Therapy of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Impact of Antihypertensive Drug Use on Bone Mineral Density and Osteoporotic Fracture - From an Epidemiological Perspective
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Renal Sympathetic Denervation and Renal Physiology
Current Clinical Pharmacology